Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data

Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data

Abstract Introduction The TNF-α blocker adalimumab is a well-proven therapy for rheumatoid arthritis (RA). A biosimilar adalimumab (ZRC-3197; Exemptia™), a ‘fingerprint match’ to reference adalimumab, has been approved for prescription in India since 2014. Here, we report on the effectiveness and to...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanjiv Kapoor, Viswanath V. Kaushik, Rahul Jain, Vijay Rao, Mihir Gharia
Formato: Artículo
Lenguaje:English
Publicado: Adis, Springer Healthcare 2019-06-01
Colección:Rheumatology and Therapy
Materias:
Adalimumab
Biosimilar
Real-life
Registry
Rheumatoid Arthritis
Acceso en línea:http://link.springer.com/article/10.1007/s40744-019-0166-2

Internet

http://link.springer.com/article/10.1007/s40744-019-0166-2

Ejemplares similares